Dual weekly therapy delivers sustained growth gains in children with achondroplasia
Weekly navepegritide combination sustains growth through 78 weeks in achondroplasia. Read what the small COACH trial shows and cannot prove.
Pharma & Biotech
Pharma & Biotech
Bezisterim Phase 2 data support anti-inflammatory approach in early Parkinson’s disease
Bezisterim improves motor, non-motor and inflammatory measures in a small Parkinson’s trial. Read what the data show and why doubts remain.
Pharma & Biotech
Aravax’s peanut allergy treatment avoids whole allergens. FDA Fast Track status puts its biggest test in focus
Aravax has secured United States Food and Drug Administration Fast Track designation for PVX108, an investigational peptide immunotherapy designed to retrain peanut-specific immune responses without containing whole peanut proteins or allergen extracts. The regulatory milestone increases the importance of Phase 2 results expected later in 2026.
Pharma & Biotech
LX2020 gains FDA RMAT status after early PKP2 heart gene therapy data
LX2020 gains FDA RMAT status after early PKP2 heart data. Read what the designation changes and why the evidence remains preliminary.
Pharma & Biotech
Acrivon moves ACR-2316 into dose expansion across six solid tumor groups
ACR-2316 enters randomized expansion after early lung cancer responses. Read how Acrivon will compare two weekly doses across six tumor groups.
Pharma & Biotech
Bria-PROS+ moves into Phase 1/2a testing with FDA clearance in prostate cancer
FDA clearance allows Bria-PROS+ to enter Phase 1/2a prostate cancer testing. Read how the off-the-shelf cellular immunotherapy works.
Pharma & Biotech
BP-205 Phase 1 data support once-daily dosing as orexin drug race intensifies
BP-205 Phase 1 data show a 25-hour half-life and support once-daily dosing as Harmony advances its orexin agonist into further clinical testing.
Pharma & Biotech
First patient dosed in BEAM-302 pivotal cohort for alpha-1 antitrypsin deficiency
BEAM-302 enters pivotal AATD testing after early base-editing data. Read how the study could support an accelerated approval pathway.
Pharma & Biotech
Rhythm Pharmaceuticals advances RM-718 after encouraging Phase 2 obesity results
Rhythm Pharmaceuticals reports an 11.6% BMI reduction with weekly RM-718 in a small hypothalamic obesity study. See what the data reveal.
Pharma & Biotech
Aravax FDA fast-track win moves PVX108 closer to its defining peanut allergy test
Aravax wins FDA Fast Track status for PVX108 as Phase 2 peanut allergy data approach. Read what the designation changes for development.